sábado, 24 de enero de 2026

The value of patient experience in multiple sclerosis research The Lancet Neurology + +... ++

The value of patient experience in multiple sclerosis research The Lancet Neurology https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00485-5/fulltext?dgcid=raven_jbs_etoc_email Feb 2026 Volume 25Number 2p115-212, e2 https://www.thelancet.com/journals/laneur/issue/vol25no2/PIIS1474-4422(26)X0002-3 Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial Prof Pierre N Tariot, MDl,* pierre.tariot@bannerhealth.com ∙ Prof Francisco S Lopera, MDa,*,† ∙ Silvia Ríos-Romenets, MDa,* ∙ Kaycee M Sink, MDb,* ∙ Margarita Giraldo-Chica, MDa ∙ Natalia Acosta-Baena, MDa ∙ et al. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00426-0/fulltext?dgcid=raven_jbs_etoc_feature_laneur Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial Prof Tom Solomon, FMedSci, PhDa,b,c,d tsolomon@liverpool.ac.uk ∙ Cory Hooper, PhDd ∙ Ava Easton, PhDd,e ∙ Anna Rosala-Hallas, MScf ∙ Bethany Facer, MScg ∙ Perry Moore, PhDc ∙ et al. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00454-5/fulltext?dgcid=raven_jbs_etoc_feature_laneur

No hay comentarios:

Publicar un comentario